{"entity":{"id":"kang-yoon-koo","kind":"person","name":"Yoon-Koo Kang","aka":[],"tldr":"Led the ATTRACTION-2 nivolumab trial and the SPOTLIGHT zolbetuximab trial, two of the defining gastric cancer studies of the decade.","summary":"Yoon-Koo Kang is Professor of Medical Oncology at Asan Medical Center in Seoul, specialising in gastric cancer and gastrointestinal stromal tumours. He led ATTRACTION-2, which established the PD-1 antibody nivolumab in late-line gastric cancer in Asia, and SPOTLIGHT, which established zolbetuximab as the first Claudin 18.2-directed therapy, two of the defining gastric cancer studies of the decade. His publications include the ATTRACTION-2 trial of nivolumab in heavily pretreated gastric or gastro-oesophageal junction cancer and the SPOTLIGHT trial of zolbetuximab plus mFOLFOX6 in Claudin 18.2-positive disease. He also led imatinib and other KIT-directed GIST studies.","asOf":"2026-09-08","links":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric"}],"tags":[],"related":[],"cancers":["gastric","sarcoma"],"sections":[],"technologies":[],"targets":["cldn18-2","pd1","kit"],"drugs":["zolbetuximab","nivolumab","imatinib"],"companies":[],"institutions":["asan-medical-center"],"pathways":[],"terms":[],"trials":["spotlight-glow"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Professor of Medical Oncology; gastric cancer and GIST","institutionId":"asan-medical-center","specialisms":["Gastric cancer","Gastrointestinal stromal tumour","Immunotherapy","Claudin 18.2"],"profiles":[{"label":"Asan Medical Center","url":"https://eng.amc.seoul.kr"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kang%20YK%5BAuthor%5D%20Asan%20gastric"}],"papers":[{"title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to two or more previous chemotherapy regimens (ATTRACTION-2)","journal":"Lancet","year":2017,"doi":"10.1016/S0140-6736(17)31827-5"},{"title":"Zolbetuximab plus mFOLFOX6 in CLDN18.2-positive, HER2-negative gastric or GEJ adenocarcinoma (SPOTLIGHT)","journal":"Lancet","year":2023,"doi":"10.1016/S0140-6736(23)00620-7"},{"title":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","journal":"The Lancet","year":2023,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SPOTLIGHT+zolbetuximab+mFOLFOX6+Shitara+Lancet"}],"orcid":"0000-0003-0783-6583"},"route":"/people/kang-yoon-koo/","neighbours":{"cancer":[{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"}],"target":[{"id":"cldn18-2","kind":"target","name":"Claudin 18.2","route":"/targets/cldn18-2/"},{"id":"kit","kind":"target","name":"KIT","route":"/targets/kit/"},{"id":"pd1","kind":"target","name":"PD-1","route":"/targets/pd1/"}],"drug":[{"id":"imatinib","kind":"drug","name":"Imatinib","route":"/drugs/imatinib/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"zolbetuximab","kind":"drug","name":"Zolbetuximab","route":"/drugs/zolbetuximab/"}],"institution":[{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","route":"/institutions/asan-medical-center/"}],"trial":[{"id":"attraction-2","kind":"trial","name":"ATTRACTION-2","route":"/trials/attraction-2/"},{"id":"spotlight-glow","kind":"trial","name":"SPOTLIGHT & GLOW","route":"/trials/spotlight-glow/"}],"paper":[{"id":"paper-spotlight-lancet-2023","kind":"paper","name":"SPOTLIGHT: zolbetuximab, the first Claudin 18.2 antibody, added to chemotherapy in gastric cancer","route":"/key-papers/paper-spotlight-lancet-2023/"}]}}